Interim CFO at Nektar Therapeutics (NKTR) files initial Form 3 ownership report

Rhea-AI Filing Summary

Nektar Therapeutics reported that Interim CFO Linda M. Rubinstein filed an initial statement of beneficial ownership as a company officer. This Form 3 filing lists her as an officer but does not report any purchases, sales, or other transactions in Nektar Therapeutics securities.

Key Terms

Interim CFO, ten percent owner, Form 3

3 terms

Interim CFO financial

""officer_title": "Interim CFO""

An interim CFO is a temporary chief financial officer hired to run a company’s finance operations during a leadership transition, a search for a permanent hire, or while specific financial issues are resolved. Investors pay attention because this person manages budgeting, financial reporting and communications with shareholders—like a substitute driver keeping a car on course—so their competence affects short‑term financial stability, the accuracy of public reports, and market confidence.

ten percent owner financial

""is_ten_percent_owner": 0"

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 05/26/2026 - 06:20 PM Accepted by SEC EDGAR 05/26/2026 - 06:20 PM Learn about SEC filing dates

FAQ

What does Linda M. Rubinstein’s Form 3 filing mean for NKTR?

The Form 3 shows that Interim CFO Linda M. Rubinstein has become a reporting officer for Nektar Therapeutics. It lists her status but reports no stock purchases, sales, or other transactions, so it is an administrative disclosure rather than a trading event.

Did the Nektar Therapeutics Interim CFO buy or sell NKTR shares in this Form 3?

No transactions are reported in this Form 3 for Nektar Therapeutics. The filing shows zero buys, zero sells, and no derivative exercises, indicating it is solely an initial ownership statement for Interim CFO Linda M. Rubinstein.

Is Linda M. Rubinstein a 10% owner of Nektar Therapeutics according to this filing?

No, the Form 3 indicates Linda M. Rubinstein is not a ten percent owner of Nektar Therapeutics. She is listed as an officer, serving as Interim CFO, with no status as a 10% beneficial owner in this disclosure.

Does this Nektar Therapeutics Form 3 show any derivative option exercises?

No derivative transactions are shown in this Form 3 for Nektar Therapeutics. The summary fields report zero exercises and no derivative positions being transacted, reinforcing that this is purely an initial reporting form for the Interim CFO.

Why are there no share counts listed for Linda M. Rubinstein in this NKTR Form 3 data?

The provided Form 3 data focuses on classification and transaction counts, all of which are zero. It identifies Linda M. Rubinstein as Interim CFO but does not include detailed holding entries or specific share counts in this excerpt.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rubinstein Linda M

(Last) (First) (Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/15/2026

3. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Ex-24 Power of Attorney

No securities are beneficially owned.

	Elizabeth Zhang, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)